NewEdge Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

NewEdge Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.76K	Hold	109	–	–	﹤0.01%	3859
2026 Q1	$2.43K	Sell	109 -100	-48%	-$2.39K	﹤0.01%	3766
2025 Q4	$5.58K	Hold	209	–	–	﹤0.01%	3646
2025 Q3	$4.46K	Hold	209	–	–	﹤0.01%	3571
2025 Q2	$4.51K	Hold	209	–	–	﹤0.01%	3435
2025 Q1	$3.47K	Hold	209	–	–	﹤0.01%	3396
2024 Q4	$3.83K	Hold	209	–	–	﹤0.01%	3303
2024 Q3	$3.21K	Hold	209	–	–	﹤0.01%	3296
2024 Q2	$3.4K	Hold	209	–	–	﹤0.01%	3205
2024 Q1	$3.86K	Hold	209	–	–	﹤0.01%	3226
2023 Q4	$6.54K	Buy	209 +109	+109%	+$2.6K	﹤0.01%	3024
2023 Q3	$2.08K	Sell	100 -100	-50%	-$2.72K	﹤0.01%	3037
2023 Q2	$4.79K	Hold	200	–	–	﹤0.01%	2834
2023 Q1	$3.76K	Sell	200 -209	-51%	-$3.98K	﹤0.01%	2867
2022 Q4	$3.33K	Buy	+409	New	+$6.39K	﹤0.01%	2716

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NewEdge Advisors's ACAD Position: Q2 2026 in Review

NewEdge Advisors held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 109 shares worth $2.76K. The position accounts for ﹤0.01% of the portfolio, ranked #3859.

NewEdge Advisors first reported a position in ACAD in Q4 2022 and has held it in 15 quarters since. The position peaked at $6.54K in Q4 2023. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

NewEdge Advisors held 109 shares of Acadia Pharmaceuticals worth $2.76K as of Q2 2026.
NewEdge Advisors left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
Acadia Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3859 holding.
NewEdge Advisors first reported a position in Acadia Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
NewEdge Advisors's Acadia Pharmaceuticals position peaked at $6.54K in Q4 2023.
353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.